Referenzen
Produkte Transfektion
Kostenlose Testsamples
Anwendungshinweise:
Im „Transfection Reagent Selection Guide“ können Sie durch Filterfunktionen z.B. für Ihre Kombination aus zu transfizierender Zelle und Nukleinsäure die Liste vorhandener Referenzen durchsuchen. Ebenso können Sie im Feld „Referenzen durchsuchen“ am Anfang der Seite mit passenden Schlagwörtern zu einem Ergebnis gelangen. Eine Referenz zeigt an, dass das gefundene Transfektionsreagenz bereits erfolgreich für die entsprechende Anwendung verwendet wurde. Im Idealfall sind getestete Transfektionsparameter und Transfektionseffizienzen angegeben.
Keine Referenz? > Allgemeine Auswahlhilfe
Wenn Sie keine Referenz gefunden haben, heißt das nicht, dass kein passendes Reagenz zur Verfügung steht, sondern lediglich, dass bisher keine Erfahrungsberichte vorliegen. In diesem Falle kann durch eine Vorauswahl ein erfolgsversprechendes Transfektionsreagenz ausgewählt (Allgemeine Auswahlhilfe) und letztendlich ausgetestet (Kostenlose Testsamples) werden. Wenn Sie einen Erfahrungsbericht für uns schreiben möchten machen wir Ihnen ein Angebot für eine Gegenleistung.
CELL TYPE | DESCRIPTION OF CELL TYPE | CAT.NO. | SPECIES | ORIGIN OF CELLS | COMMON CELL TYPE | GROWTH PROPERTIES | NUCLEIC ACID / DELIVERED MOLECULE | APPLICATION | PRODUCT | REFERENCE TYPE | BIBLIOGRAPHIC DATA | LINK | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
HEK293 EBNA1 |
Human embryonic kidney cell line stably expressing Epstein-Barr viral nuclear antigen 1 (EBNA1) (derivat of HEK293) | Human | urinary system | cell line | adherent | plasmid | stable transfection | Metafectene | publication | O. Gires et al., Anticancer Res, Nov 2004; 24: 3715 - 3722 | Link | ||
HEK293-D2089 |
Human embryonic kidney cell line | Human | urinary system | cell line | adherent | plasmid | virusproduction | Metafectene | publication | V. Mordasini et al., Oncotarget, 2017, 8 ( 4): 6461-6474 | Link | ||
HEK293-rB95.8 |
Human embryonic kidney cell line (derivat of HEK293) | Human | urinary system | cell line | adherent | plasmid | virusproduction | Metafectene | publication | J. Rac et al., PLoS ONE, 2015, 10(4): e0123645; doi:10.1371/journal.pone.0123645 | Link | ||
HEK293-rB95.8 |
Human embryonic kidney cell line (derivat of HEK293) | Human | urinary system | cell line | adherent | plasmid | cotransfection (plasmid/plasmid) | Metafectene | publication | J. Rac et al., PLoS ONE, 2015, 10(4): e0123645; doi:10.1371/journal.pone.0123645 | Link | ||
HEK293N |
Human embryonic kidney cell line | Human | urinary system | cell line | adherent | plasmid | Metafectene | publication | T. Bourquard et al., J. Immunol., 2018, ji1701722, DOI: https://doi.org/10.4049/jimmunol.1701722 | ||||
HEK293TN |
Human embryonic kidney cell line (derivat of HEK293) | Human | urinary system | cell line | adherent | plasmid | virusproduction | Metafectene | publication | L. M. Williams, Dissertation, 2014, Royal College of Surgeons in Ireland | Link | ||
HEK293TN |
Human embryonic kidney cell line (derivat of HEK293) | Human | urinary system | cell line | adherent | plasmid | virusproduction | Metafectene | publication | F. Walter, Dissertation, 2014, Royal College of Surgeons in Ireland | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene | publication | X. M. M. Weyel, Dissertation, 2018, Goethe- Universität in Frankfurt am Main | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | application note | ![]() |
|||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | S. Kobe de Oliveira et al., J. Biol. Chem., May 2007; 282: 13656 - 13663 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene | publication | L. T. Jennelle, Dissertation, 2013, George Washington University | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | W. Kim et al., J. Biol. Chem., 287 (8): 5278–5289, DOI 10.1074/jbc.M111.281709 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | V. Mikat et al., RNA, Dec 2007; 13: 2341 - 2347 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | stable transfection | Metafectene | publication | S.-B. M. Varda et al., 2012, WO 2007/043049 | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | N. Mukhamedova et al., J. Lipid Res., Nov 2008; 49: 2312 - 2322 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | cotransfection (plasmid/plasmid) | Metafectene | publication | J. Schulz et al., Scientific Reports, 2018, 8: 2395, DOI:10.1038/s41598-018-19201-8 | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | M. M. Nalaskowski et al., J. Biol. Chem., Feb 2011; 286: 4500 - 4510 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene | publication | C. Benincá et al., J. Med. Genet., 2021, 58: 155–167, doi:10.1136/jmedgenet-2020-106861 | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | M. C. Mayer et al., J. Immunol., Oct 2013; 191: 3594 - 3604 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | L. Rampoldi et al., Hum. Mol. Genet., Dec 2003; 12: 3369 - 3384 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | plasmid | Metafectene | publication | P. Aridon, Parkinsonism and Related Disorders, 2016, 31:135-138, doi.org/10.1016/j.parkreldis.2016.08.016 | ||||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene | application note | ![]() |
||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | R. Berro et al., J. Virol., Apr 2006; 80: 3189 - 3204 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | L. Vay et al., J. Physiol., 2007, 580.1, 39-49 | |||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | T.-H. Kang et al., Mol. Cell. Biol., Dec 2007; 27: 8533 - 8546 | Link |